Advanced search
Publication Cover
Modern Rheumatology Volume 27, 2017 - Issue 2
Journal homepage
1,021
Views
12
CrossRef citations to date
0
Altmetric
Original Article

Pharmacoeconomic analysis of biological disease modifying antirheumatic drugs in patients with rheumatoid arthritis based on real-world data from the IORRA observational cohort study in Japan

Eiichi TanakaInstitute of Rheumatology, Tokyo Women’s Medical University, Tokyo, JapanCorrespondence[email protected]
,
Eisuke InoueInstitute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
,
Rei YamaguchiInstitute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
,
Yoko ShimizuInstitute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
,
Akiko KobayashiInstitute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
,
Naoki SugimotoInstitute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
,
Daisuke HoshiInstitute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
,
Kumi ShidaraInstitute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
,
Eri SatoInstitute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
,
Yohei SetoInstitute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
,
Ayako NakajimaInstitute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
,
Shigeki MomoharaInstitute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
,
Atsuo TaniguchiInstitute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
&
Hisashi YamanakaInstitute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
 show all
Pages 227-236 | Received 14 Mar 2016, Accepted 31 May 2016, Published online: 29 Jul 2016

Citations (12)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Sajith Kumar & Bhavani Shankara Bagepally. (2023) Cost-effectiveness of tumor necrosis factor-alpha inhibitors: a systematic review and meta-analysis of cost-utility studies. Expert Review of Pharmacoeconomics & Outcomes Research 0:0, pages 1-14.
Read now
Yoshiyuki Abe, Keigo Saeki, Hiroaki Dobashi, Tamihiro Kawakami, Taichi Hayashi, Masaki Kobayashi, Shinya Kaname, Masayoshi Harigai & Naoto Tamura. (2021) Clinical characteristics and social productivity levels of patients with malignant rheumatoid arthritis based on a nationwide clinical database in Japan: annual survey from 2003 to 2013. Modern Rheumatology 31:3, pages 621-628.
Read now

Articles from other publishers (10)

Masataka Kuwana, Naoto Tamura, Shinsuke Yasuda, Keishi Fujio, Ayako Shoji, Hiroko Yamaguchi, Katsuhiko Iwasaki, Misako Makishima, Yuichi Kawata, Katsuhisa Yamashita & Ataru Igarashi. (2023) Cost-effectiveness analyses of biologic and targeted synthetic disease-modifying anti-rheumatic diseases in patients with rheumatoid arthritis: Three approaches with a cohort simulation and real-world data. Modern Rheumatology 33:2, pages 302-311.
Crossref
Hisashi Yamanaka, Mitsumasa Kishimoto, Nobuo Nishijima, Katsuhisa Yamashita, Junnosuke Matsushima, Jacqueline O’Brien, Taylor Blachley, Melissa Eliot, Zachary Margolin, Swapna S Dave & Yoshiya Tanaka. (2023) Socioeconomic impact of treatment with biological disease–modifying antirheumatic drugs in Japanese patients with rheumatoid arthritis. Modern Rheumatology.
Crossref
Eiichi Tanaka, Eisuke Inoue, Ayako Shoji, Jonas Nilsson, Christos Papagiannopoulos, Devender Dhanda, Yuri Yoshizawa, Mai Abe, Kumiko Saka, Eri Sugano, Naohiro Sugitani, Moeko Ochiai, Rei Yamaguchi, Katsunori Ikari, Hisashi Yamanaka & Masayoshi Harigai. (2022) Cost-consequence of abatacept as first-line therapy in Japanese rheumatoid arthritis patients using IORRA real-world data. PLOS ONE 17:11, pages e0277566.
Crossref
Ryoko Sakai, Eiichi Tanaka, Eisuke Inoue, Minako Sato, Masaru Tanaka, Katsunori Ikari, Hisashi Yamanaka & Masayoshi Harigai. (2022) Association between patient-reported outcomes and impairments in work and activity in patients with rheumatoid arthritis in clinical remission: A retrospective analysis using the IORRA database. Modern Rheumatology.
Crossref
Takashi Ohashi. (2022) The impact of monoclonal antibody drugs on healthcare economics in the treatment of multiple sclerosis and neuromyelitis optica spectrum disorders. Clinical and Experimental Neuroimmunology 13:3, pages 166-171.
Crossref
Ryoko Sakai, Eiichi Tanaka, Eisuke Inoue, Minako Sato, Masaru Tanaka, Katsunori Ikari, Hisashi Yamanaka & Masayoshi Harigai. (2022) Subjective symptoms contributing to the quality of life of rheumatoid arthritis patients with clinical remission from the IORRA database. Modern Rheumatology.
Crossref
Juan Zhao, Wei Zhou, Yangfeng Wu, Ping Ji, Li Yang, Xiaoyan Yan & Zhuoli Zhang. (2021) The efficacy, safety and cost-effectiveness of hydroxychloroquine, sulfasalazine, methotrexate triple therapy in preventing relapse among patients with rheumatoid arthritis achieving clinical remission or low disease activity: the study protocol of a randomized controlled clinical Trial (ESCoRT study). BMC Medical Informatics and Decision Making 21:1.
Crossref
Z. Kevin Lu, Xiaomo Xiong, Taiying Lee, Jun Wu, Jing Yuan & Bin Jiang. (2021) Big Data and Real-World Data based Cost-Effectiveness Studies and Decision-making Models: A Systematic Review and Analysis. Frontiers in Pharmacology 12.
Crossref
Yoshiya Tanaka & Takeshi Ohira. (2018) Mechanisms and therapeutic targets for bone damage in rheumatoid arthritis, in particular the RANK-RANKL system. Current Opinion in Pharmacology 40, pages 110-119.
Crossref
Hisashi Yamanaka, Eiichi Tanaka, Ayako Nakajima, Takefumi Furuya, Katsunori Ikari & Atsuo Taniguchi. (2017) Achievements from a large cohort study of rheumatoid arthritis関節リウマチの大規模コホート研究とその成果. Nihon Naika Gakkai Zasshi 106:12, pages 2638-2644.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.